Journal
NANOMEDICINE
Volume 10, Issue 8, Pages 1233-1246Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.14.226
Keywords
cancer; hollow mesoporous silica nanoparticles; image-guided drug delivery; PET; positron emission tomography; theranostics
Funding
- University of Wisconsin-Madison
- National Institutes of Health [NIBIB/NCI 1R01CA169365, P30CA014520, T32GM08349]
- Department of Defense [W81XWH-11-1-0644]
- American Cancer Society [125246-RSG-13-099-01-CCE]
- Fulbright Scholar Program [1831/FNPDR/2013]
Ask authors/readers for more resources
Aim: Development of multifunctional and well-dispersed hollow mesoporous silica nanoparticles (HMSNs) for tumor vasculature targeted drug delivery and PET imaging. Materials & methods: Amine functionalized HMSNs (150-250 nm) were conjugated with a macrocyclic chelator, (S)-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triaceticacid (NOTA), PEGylated and loaded with antiangiogenesis drug, Sunitinib. Cyclo(Arg-Gly-Asp-D-Tyr-Lys) (cRGDyK) peptide was attached to the nanoconjugate and radiolabeled with Cu-64 for PET imaging. Results: Cu-64-NOTA-HMSN-PEG-cRGDyK exhibited integrin-specific uptake both in vitro and in vivo. PET results indicated approximately 8% ID/g uptake of targeted nanoconjugates in U87MG tumors, which correlated well with ex vivo and histological analyses. Enhanced tumor-targeted delivery of sunitinib was also observed. Conclusion: We successfully developed tumor vasculature targeted HMSNs for PET imaging and image-guided drug delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available